Hirsch G, Rey G
Strahlentherapie. 1978 Jul;154(7):495-8.
Within less than one year, our hospital received three cases of malignant manifestation in case of multiple neurofibromatosis. If the histological findings and the neurogenic origin of the malignant tumor are evaluated very critically, the malignant suppression of the differentiation of one or more neurofibromas in case of multiple neurofibromatosis must be considered as occuring very rarely. If in case of a neurofibromatosis a malignant manifestation is found, it has to be examined very carefully by tissue specimens of numerous spots (Loehr and Willebrand), furthermore the neurogenic origin must be ensured (Zuelch). There are three clinical possibilities: 1. Sarcomatous degeneration of a neurofibroma with demonstrable neurogenic origin. 2. Histological appearence of a malignant suppression of the differntiation of a neurofibroma with benign clinical course. 3. Independent sarcoma as second disease without original connection to an existing multiple neurofibromatosis.--A critical evaluation of our cases showed that there was only one case of malignant tumor with neurogenic origin, namely a neurofibrosarcoma originating from a multiple neurofibromatosis.
在不到一年的时间里,我院收治了三例多发性神经纤维瘤病出现恶性表现的病例。如果对恶性肿瘤的组织学发现和神经源性起源进行非常严格的评估,那么在多发性神经纤维瘤病中,一个或多个神经纤维瘤分化的恶性抑制必须被视为极其罕见的情况。如果在神经纤维瘤病病例中发现恶性表现,必须通过多个部位的组织标本(勒尔和维勒布兰德)进行非常仔细的检查,此外还必须确保其神经源性起源(聚尔希)。存在三种临床可能性:1. 具有可证实神经源性起源的神经纤维瘤肉瘤样变性。2. 神经纤维瘤分化恶性抑制的组织学表现且临床病程为良性。3. 作为第二种疾病的独立肉瘤,与现有的多发性神经纤维瘤病无原始关联。——对我们病例的严格评估表明,只有一例具有神经源性起源的恶性肿瘤,即源自多发性神经纤维瘤病的神经纤维肉瘤。